IL144413A0 - Pharmaceutical compositions comprising a tnf antagonist - Google Patents

Pharmaceutical compositions comprising a tnf antagonist

Info

Publication number
IL144413A0
IL144413A0 IL14441300A IL14441300A IL144413A0 IL 144413 A0 IL144413 A0 IL 144413A0 IL 14441300 A IL14441300 A IL 14441300A IL 14441300 A IL14441300 A IL 14441300A IL 144413 A0 IL144413 A0 IL 144413A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
tnf antagonist
tnf
antagonist
pharmaceutical
Prior art date
Application number
IL14441300A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL144413(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL144413A0 publication Critical patent/IL144413A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14441300A 1999-01-22 2000-01-19 Pharmaceutical compositions comprising a tnf antagonist IL144413A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101194A EP1022027A1 (fr) 1999-01-22 1999-01-22 Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
PCT/IB2000/000052 WO2000043031A1 (fr) 1999-01-22 2000-01-19 Antagonistes de facteurs de necroses tumorales et utilisation de ceux-ci dans les cas d'endometriose

Publications (1)

Publication Number Publication Date
IL144413A0 true IL144413A0 (en) 2002-05-23

Family

ID=8237393

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14441300A IL144413A0 (en) 1999-01-22 2000-01-19 Pharmaceutical compositions comprising a tnf antagonist
IL144413A IL144413A (en) 1999-01-22 2001-07-18 Pharmaceutical preparations containing TNF antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144413A IL144413A (en) 1999-01-22 2001-07-18 Pharmaceutical preparations containing TNF antagonist

Country Status (30)

Country Link
US (2) US6663865B1 (fr)
EP (2) EP1022027A1 (fr)
JP (1) JP4601176B2 (fr)
KR (2) KR20060128056A (fr)
CN (2) CN1212152C (fr)
AR (1) AR022251A1 (fr)
AT (1) ATE242002T1 (fr)
AU (1) AU771964B2 (fr)
BG (1) BG65556B1 (fr)
BR (1) BR0008182A (fr)
CA (1) CA2356737C (fr)
CZ (1) CZ302866B6 (fr)
DE (1) DE60003152T2 (fr)
DK (1) DK1143997T3 (fr)
EA (1) EA003927B1 (fr)
EE (1) EE05543B1 (fr)
ES (1) ES2200808T3 (fr)
HK (2) HK1043059B (fr)
HU (1) HU226149B1 (fr)
IL (2) IL144413A0 (fr)
NO (1) NO328814B1 (fr)
NZ (1) NZ512585A (fr)
PL (1) PL204713B1 (fr)
PT (1) PT1143997E (fr)
SI (1) SI1143997T1 (fr)
SK (1) SK287313B6 (fr)
TR (1) TR200102107T2 (fr)
UA (1) UA78483C2 (fr)
WO (1) WO2000043031A1 (fr)
ZA (1) ZA200105263B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010180B1 (ru) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1709965A3 (fr) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methode pour le traitement des maladies reliées au cytokine
US7082134B1 (en) * 2002-01-18 2006-07-25 Juniper Networks, Inc. Redirect checking in a network device
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DE60325275D1 (de) * 2003-02-07 2009-01-22 Austria Wirtschaftsservice Gmbh Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
GB0327112D0 (en) 2003-11-21 2003-12-24 Clincial Designs Ltd Dispenser and reservoir
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
US20080014172A1 (en) * 2004-05-28 2008-01-17 Applied Research Systems Ars Holding N.V. Use of Il-17 in the Treatment of Fertility-Related Disorders
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
CN101282646B (zh) * 2005-07-12 2013-03-27 Dmi生物科学公司 治疗疾病的方法和产品
WO2008149147A2 (fr) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, domaines variables d'anticorps et antagonistes
AU2010264525B2 (en) * 2009-06-22 2015-04-02 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
PT2554174E (pt) * 2009-06-22 2015-12-15 Ampio Pharmaceuticals Inc Método para o tratamento de doenças
EA201500752A1 (ru) 2012-12-19 2016-05-31 Ампио Фармасьютикалс, Инк. Способ лечения заболеваний
WO2016140921A1 (fr) 2015-03-02 2016-09-09 180 Therapeutics Lp Méthode de traitement d'un trouble fibrotique localisé à l'aide d'un antagoniste de l'il-33

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037805A (en) * 1989-03-20 1991-08-06 The Salk Institute For Biological Studies Methods of contraception
US20040120952A1 (en) * 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1681305A3 (fr) * 1991-03-18 2008-02-27 New York University Anticorps monoclonaux et chimères contre le facteur humain de nécrose de tumeurs
CA2123593C (fr) * 1992-09-15 2000-03-14 Craig A. Smith Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
US5389657A (en) * 1993-02-01 1995-02-14 Free Radical Sciences Corporation Method for treating infertility
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5747532A (en) * 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5710247A (en) * 1996-03-19 1998-01-20 Abbott Laboratories Process and intermediates for the synthesis of LHRH antagonists
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
ATE429241T1 (de) * 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
BR0008182A (pt) 2001-11-06
SK287313B6 (sk) 2010-06-07
EP1143997B1 (fr) 2003-06-04
EA003927B1 (ru) 2003-10-30
US20040057954A1 (en) 2004-03-25
KR20060128056A (ko) 2006-12-13
NO20013577D0 (no) 2001-07-19
CA2356737A1 (fr) 2000-07-27
WO2000043031A1 (fr) 2000-07-27
PL204713B1 (pl) 2010-02-26
JP2002535284A (ja) 2002-10-22
JP4601176B2 (ja) 2010-12-22
CN1698894A (zh) 2005-11-23
CN1212152C (zh) 2005-07-27
HK1082690A1 (en) 2006-06-16
HK1043059A1 (en) 2002-09-06
CZ302866B6 (cs) 2011-12-21
PL350002A1 (en) 2002-10-21
EP1022027A1 (fr) 2000-07-26
CA2356737C (fr) 2010-03-23
PT1143997E (pt) 2003-10-31
BG105691A (en) 2002-02-28
KR20010101397A (ko) 2001-11-14
NO20013577L (no) 2001-08-29
EE05543B1 (et) 2012-06-15
TR200102107T2 (tr) 2001-12-21
AR022251A1 (es) 2002-09-04
BG65556B1 (bg) 2008-12-30
ES2200808T3 (es) 2004-03-16
AU771964B2 (en) 2004-04-08
DE60003152T2 (de) 2004-03-25
EA200100799A1 (ru) 2001-12-24
ZA200105263B (en) 2002-06-26
HK1043059B (zh) 2005-11-18
DE60003152D1 (de) 2003-07-10
HU226149B1 (en) 2008-05-28
IL144413A (en) 2009-05-04
SI1143997T1 (en) 2003-12-31
CZ20012656A3 (cs) 2002-02-13
CN1337883A (zh) 2002-02-27
CN100594932C (zh) 2010-03-24
EP1143997A1 (fr) 2001-10-17
SK10292001A3 (sk) 2001-12-03
UA78483C2 (en) 2007-04-10
NO328814B1 (no) 2010-05-18
US6663865B1 (en) 2003-12-16
ATE242002T1 (de) 2003-06-15
KR100685106B1 (ko) 2007-02-22
EE200100378A (et) 2002-10-15
AU1997300A (en) 2000-08-07
NZ512585A (en) 2003-08-29
HUP0105103A3 (en) 2004-08-30
DK1143997T3 (da) 2003-09-15
HUP0105103A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
GB2358582B (en) Pharmaceutical compositions
PL351387A1 (en) Pharmaceutical composition
HUP0300582A3 (en) Pharmaceutical compositions
IL144413A0 (en) Pharmaceutical compositions comprising a tnf antagonist
AU6219601A (en) Pharmaceutical compositions
HK1044476A1 (en) Medicinal compositions
HK1064601A1 (en) Pharmaceutical compositions comprising amlodipene maleate
GB0009584D0 (en) Pharmaceutical compositions
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (fr) Compositions medicamenteuses
AU8576801A (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
GB9904911D0 (en) Pharmaceutical compositions
GB9902651D0 (en) Pharmaceutical compositions
IL147413A0 (en) Pharmaceutical compositions comprising grf
GB9902591D0 (en) Pharmaceutical compositions
GB9902594D0 (en) Pharmaceutical compositions
GB9920652D0 (en) Pharmaceutical compositions